Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Inhaler Overuse Linked to Cardiovascular Death Risk

Analysis based on 6 articles · First reported Aug 26, 2026 · Last updated Sep 10, 2026

Sentiment
-5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The findings could modestly weigh on makers of short-acting bronchodilator inhalers if they prompt tighter prescribing and greater use of maintenance therapies, while supporting demand for respiratory and cardiovascular monitoring. Overall market impact is limited because the study is observational, does not establish causation, and does not change any regulatory or commercial status.

pharmaceuticals healthcare

A large observational study published in ERJ Open Research found that overuse of short-acting reliever inhalers among asthma and COPD patients is associated with higher risks of cardiovascular disease and death, including heart failure, heart attack and ischemic stroke. The research, led by Lies Lahousse of Ghent University in Belgium and Erasmus MC in the Netherlands, analyzed real-world primary and secondary care data from more than 280,000 asthma and COPD patients in Belgium who used SABA, SAMA, both, or no short-acting bronchodilators. Compared with no use, SABA use was associated with a 12% higher risk of death in asthma patients and 14% in COPD patients, while SAMA use was associated with a 73% higher risk in asthma and 36% in COPD. Using three or more reliever inhalers per year was linked to higher mortality than using two or fewer, and patients without prior cardiovascular disease appeared particularly vulnerable. The authors caution that the observational design cannot prove causation, since frequent reliever use may itself be a marker of poorly controlled lung disease. Pavol Pobeha of the European Respiratory Society, based at Pavol Jozef Šafárik University in Slovakia, who was not involved in the research, said relievers remain essential for symptom management but called for better monitoring systems to flag overuse. The team plans further work on whether stricter adherence to maintenance treatment reduces reliever overuse and whether cardiovascular risk assessment can lower risks for these patients.

90 Lies Lahousse published study
30 Pavol Pobeha commented on study
per
Lead author of the study from Ghent University and Erasmus MC Rotterdam, whose statements framed reliever overuse as an alarm signal for uncontrolled disease and cardiovascular risk.
Importance 90.0 Sentiment 0.0
cnt
Country whose primary and secondary care records supplied the real-world data for over 280,000 asthma and COPD patients.
Importance 50.0 Sentiment 0.0
ngo
Professional body whose expert group provided independent commentary, reinforcing the call for better monitoring of reliever inhaler overuse.
Importance 40.0 Sentiment 0.0
per
Independent European Respiratory Society expert who stressed that relievers remain important while urging improved monitoring systems to detect overuse early.
Importance 35.0 Sentiment 0.0
cnt
Country affiliated with the lead author's Erasmus MC Rotterdam position, contributing to the study's institutional base.
Importance 25.0 Sentiment 0.0
oth
Slovak university hosting the independent expert who commented on the study, giving the findings additional clinical context.
Importance 20.0 Sentiment 0.0
cnt
Country where the independent commenting expert is based, providing external clinical perspective on the findings.
Importance 15.0 Sentiment 0.0
Belgium related ↔ Netherlands
Belgium related ↔ Slovakia
Netherlands related ↔ Slovakia
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.